Hans Hull, J.D., is an accomplished biotechnology executive who brings to Pliant more than 15 years of experience in corporate development, legal and operational roles. Mr. Hull was previously interim CEO of Avalanche Biotechnologies, a public gene therapy company, after serving as senior vice president of business operations for the company. During his tenure at Avalanche, he closed multiple transactions including an eight-product, $640 million collaboration with Regeneron Pharmaceuticals, and helped raise more than $300 million in private and public equity financing. Prior to Avalanche, Mr. Hull was CEO of Orthobond, a medical device startup, following an earlier career as an intellectual property attorney at Heller Ehrman LLP and life science consultant at ZS Associates.